Historique
Rapport
AB-CHMINACA. Report on the risk assessment of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) in the framework of the Council Decision on new psychoactive substances
Auteur(s) :
OEDT = EMCDDA (Observatoire européen des drogues et des dépendances = European monitoring centre for drugs and drug addiction)
Année :
2018
Page(s) :
67 p.
Langue(s) :
Anglais
Collection :
Risk assessments, 24
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Organismes
OEDT
Thésaurus mots-clés
CANNABINOIDES
;
CONTROLE DES STUPEFIANTS
;
FACTEUR DE RISQUE
;
DROGUES DE SYNTHESE
;
PHARMACOLOGIE
;
TYPE D'USAGE
;
EFFET SECONDAIRE
;
TOXICITE
;
INTOXICATION
;
MORTALITE
;
SURVEILLANCE EPIDEMIOLOGIQUE
Thésaurus géographique
EUROPE
Note de contenu :
TABLE OF CONTENTS:
- Foreword.
- EMCDDA actions on monitoring and responding to new drugs Europol-EMCDDA Joint Report on AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) - a summary.
- Risk Assessment Report on a new psychoactive substance: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA).
- Technical report on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA).
- Participants of the risk assessment meeting, 7-8 November 2017.
- Foreword.
- EMCDDA actions on monitoring and responding to new drugs Europol-EMCDDA Joint Report on AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) - a summary.
- Risk Assessment Report on a new psychoactive substance: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA).
- Technical report on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA).
- Participants of the risk assessment meeting, 7-8 November 2017.
Résumé :
This publication presents the data and findings of the risk assessment on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place AB-CHMINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.